Grigor'eva N Iu
Kardiologiia. 2009;49(7-8):38-41.
Effect of therapy with 1-adrenoblocker bisoprolol and inhibitor of If channels ivabradine on parameters of 24-hour ECG monitoring (24hECGM) was studied in 64 patients with ischemic heart disease (stable angina) and chronic obstructive pulmonary disease (COPD). At the first stage all patients received bisoprolol. Parameters of external respiration function (ERF) and 24h ECG were registered before and after 4 months of bisoprolol administration. At stage 2 indications were determined for inclusion of ivabradine in the treatment scheme. At the background of therapy with bisoprolol we obtained significant lowering of heart rate (HR) both during day and night, as well as significant diminution of magnitude and duration of ischemic ST depression. In 44% of patients target HR range was not achieved. This conditioned the necessity to administer ivabradine. Therapy of patients with stable angina and concomitant COPD should begin with cardioselective -adrenoblockers (bisoprolol). Incorporation of inhibitor of If channels ivabradine in the treatment scheme is indicated if during treatment with -adrenoblockers average 24 hour HR according to data of 24hECGM exceeds 70 beats/min and deterioration of bronchial conductance according to ERF data occurs.
在64例缺血性心脏病(稳定型心绞痛)合并慢性阻塞性肺疾病(COPD)的患者中,研究了1-肾上腺素能阻滞剂比索洛尔和If通道抑制剂伊伐布雷定治疗对24小时心电图监测(24hECGM)参数的影响。在第一阶段,所有患者均接受比索洛尔治疗。在给予比索洛尔4个月前后,记录患者的外呼吸功能(ERF)参数和24h心电图。在第二阶段,确定将伊伐布雷定纳入治疗方案的指征。在比索洛尔治疗的基础上,我们观察到患者白天和夜间的心率(HR)均显著降低,缺血性ST段压低的幅度和持续时间也显著缩短。44%的患者未达到目标心率范围。这使得有必要给予伊伐布雷定。对于稳定型心绞痛合并COPD的患者,治疗应从心脏选择性β-肾上腺素能阻滞剂(比索洛尔)开始。如果根据24hECGM数据,在使用β-肾上腺素能阻滞剂治疗期间患者24小时平均心率超过70次/分钟,且根据ERF数据显示支气管传导功能恶化,则表明在治疗方案中应加入If通道抑制剂伊伐布雷定。